InvestorsHub Logo

SJOGRINGO

10/18/17 10:55 AM

#63 RE: SJOGRINGO #62

Living Cell Technologies: Impending Phase IIb Results For NTCELL, A Disease-Modifying Agent For Parkinson's https://seekingalpha.com/article/4109231?source=ansh $LVCLY, $ACAD